News

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Lilly’s Zepbound Trims More Belly Fat Than Novo’s Wegovy
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
KDFW5d
Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Novo Replaces CEO Jorgensen After Lilly Rivalry Hits Shares
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...
Eli Lilly, compounders partly to blame for Novo CEO’s ouster
CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...